As the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...

Global economic shocks from trade disruptions and geopolitical tensions are reshaping resilience, according to Raghuram Rajan. He stresses ...

The most impactful AI products of 2026 aren't built to do everything; they're built to solve one problem exceptionally well. The ET Most In...

Rising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...

On Thursday evening, US President Trump said he would “hit Iran hard tonight”. Then, as the world waited with bated breath, came the announ...

There are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...

Cancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...

India has a structural advantage in quantum computing. Its size inherently creates challenging optimisation issues, offering a practical te...

Even in normal times it is futile to try and guess the outcome of most global events. But in the New World Order, it makes no sense at all ...

For the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...

As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...

After the correction, the street will reach a stage where, if a company delivers numbers, there will be enough money waiting to move into t...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...

Cipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...

As Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...

President Donald Trump is expanding access to affordable medicines. The government website TrumpRx.gov will now list over 600 generic drugs...